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Empirical Treatment of Acute Purdent Meningitis 
Benito Almirante, MD;* and Jo& A. Capdevila, MD* 
Acute purulent meningitis, a disease with an associated 
mortality rate of 25 to 33%,l,* is still an important prob- 
lem worldwide. Despite treatment with potent bacteri- 
cidal drugs, elderly patients, patients with altered 
consciousness, and patients suffering from convulsions at 
admission are at a high risk of death.’ The mortality rate 
in Streptococcus pneumoniae meningitis, especially in 
adults, is as high as 3O%.3,4 In the majority of geographic 
areas, Haemophilus injikenzae, Streptococcus pneu- 
moniae, and Neisseria meningitidis are the causal agents 
in more than 80% of cases of acute purulent meningitis 
with established etiology. Until vaccination against these 
microorganisms becomes common practice, physicians 
must take them into consideration when selecting empir- 
ical treatment for acute purulent meningitis. Other 
microorganisms, including Listeria monocytogenes, 
enteric gram-negative bacilli, staphylococci and Group I3 
streptococci, are far less frequently the cause of bacter- 
ial meningitis and are related to particular clinical set- 
tings, such as immunosuppressed hosts, the elderly, 
alcoholics, neonates, patients with malignancy, cortico- 
steroid therapy, previous neurosurgery, or head trauma, 
and cerebrospinal fluid (CSF) shunts. 
Favorable outcome in purulent meningitis is clearly 
related to early institution of effective antimicrobial treat- 
ment. Diagnosis is based on the observation of a turbid 
CSF with polymorphonuclear pleocytosis, a decrease in 
glucose levels, and elevated protein levels5 One report 
has shown that CSF glucose results under 34 mg/dL, pro- 
tein levels over 220 mg/dL, or neutrophils over lSO/mL 
have a positive predictive value of 99% for the diagnosis 
of bacterial meningitis6 Therapy should not be delayed 
the 24 hours or more required for CSF cultures and 
antimicrobial susceptibility testing. 
Gram stain of CSF is an important tool for guiding ini- 
tial antimicrobial treatment when results obtained are 
positive; unfortunately, only 60 to 90% of acute bacterial 
meningitis cases show positive results with this test.’ In 
patients with previous antibiotic treatment, the yield on 
smear is reduced to 40 to GO%, and the yield on culture 
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of-CSF, to Xl%,5 The concentration of bacteria present in 
the CSF determines the success of Gram stain detection: 
concentrations below 1 O3 colony-forming units (CFU)/mL 
are associated with positive Gram stain in only 25% of 
cases, whereas concentrations over lo5 CFU/mL show 
positive results in 95%.* 
The choice of empirical treatment in patients with 
acute purulent meningitis and negative Gram stains is 
based on the age of the patient, associated conditions, 
underlying diseases, and epidemiologic data. 
The recommendations concerning antimicrobial use 
in the empirical treatment of pyogenic meningitis have 
been modified according to the changes in patterns of 
sensitivity of the most frequent etiologic agents. In recent 
years, strains of meningococci that are relatively resistant 
to penicillin, with minimum inhibitory concentrations 
(MICs) ranging from 0.1 to 1.0 pg/mL, have been 
described. Although the prevalence of these strains in 
specific countries, such as Spain and the United King- 
dom, can reach 20% of isolates,9J0 the outcome of menin- 
gitis caused by relatively resistant strains treated with 
standard doses of penicillin has been satisfactory; thus the 
clinical significance of these resistant strains remains 
uncertain. Moreover, in many parts of the world the 
prevalence of penicillin-resistant meningococci is not 
alarming; in recent studies from the United States, the 
prevalence was less than 3%.‘* All the third-generation 
cephalosporins, and especially ceftriaxone, have main- 
tained excellent activity against strains moderately resis- 
tant to penicillin, l3 thus doses of 50 to 100 mg/kg per day 
(not to exceed 4 g per day) can be a good therapeutic 
alternative for meningococcal meningitis in areas with a 
high prevalence of strains that are relatively resistant to 
penicillin. l l 
The resistance to ampicillin, due to beta-lactamase 
production in H. in.uenzae strains from patients with 
meningitis, ranges from 30 to 50%.3,14J5 Many of these 
isolates are also resistant to chloramphenicol. Moreover, 
there is clinical evidence that chloramphenicol is less 
effective than the third-generation cephalosporins, even 
in cases of meningitis caused by chloramphenicol-sensi- 
tive strains.16 Recent studies have demonstrated the clear 
superiority of the third-generation cephalosporins (cef- 
triaxone or cefotaxime) for the treatment of H. in&en- 
zae meningitis, presumably related to faster sterilization 
of the CSF and fewer neurologic sequelae.17Js As an alter- 
native to penicillin, a third-generation cephalosporin, 
rather than chloramphenicol should be considered as the 
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empirical antibiotic of choice in treating acute bacterial 
meningitis in children. 
Strains of S.pneumoniae resistant to penicillin and 
other antibiotics have rapidly spread throughout the 
world, reaching a prevalence of over 50% in some coun- 
tries.19 Resistance seems to have emerged, initially, as a 
slight increase in the prevalence of moderately resistant 
isolates; this was followed by a phase of rapid increase 
in the number of isolates with moderate and high resis- 
tance. The development of this increased qualitative and 
quantitative resistance to penicillin has been associated 
with the high use of B-lactam antibiotics within the com- 
munity.20 There also is clear evidence pointing to dis- 
semination of clones of resistant isolates, even between 
countries thousands of miles apartz1J2 These observa- 
tions support the in vitro data showing that resistance to 
penicillin is a stable characteristic of the bacterium that 
can persist and disseminate in the absence of pressure 
from selective antibiotics. 
The broad-spectrum cephalosporins (cefotaxime and 
ceftriaxone) have been considered the empirical treat- 
ment of choice for meningitis of probable pneumococ- 
cal etiology, in children as well as adults. However, in 
recent years a number of therapeutic failures have been 
documented in cases of meningitis due to strains of S. 
pneumoniae with MICs between 0.5 and 32 ug/mL.23 
Because of this, the American National Committee for 
Clinical Laboratory Standards (NCCLS) now considers 
CSF-isolated strains of S.pneumoniae with MICs equal to 
or greater than 1 yg/mL to be resistant to third-genera- 
tion cephalosporins. ** There are reports from a few coun- 
tries on the incidence of S. pneumoniae strains that 
would, by this definition be considered resistant to third- 
generation cephalosporins. 25 The reported incidence of 
S. pneumoniae resistant to the third-generation 
cephalosporins ranges from 9 to 17%26,27; however, CSF 
isolates with MICs higher than 2 pg/mL are rare. 
A recent study described the successful treatment 
with high doses of cefotaxime (300 mg/kg/d, maximum 
24 g/d) of cases of S. pneumoniae meningitis due to 
strains with decreased sensitivity to broad-spectrum 
cephalosporins. 28 Preliminary studies suggest that addi- 
tion of vancomycin may not offer any therapeutic bene- 
fits in the treatment of meningitis caused by these 
isolates; further studies are needed of the role of van- 
comycin.29 Currently, the regimen of elevated doses of 
cefotaxime or ceftriaxone seems most suitable for the 
empirical treatment of meningitis of probable pneumo- 
coccal etiology. Other 1S-lactam antibiotics that are active 
against pneumococcal strains considered to be resistant 
to third-generation cephalosporins, such as meropenem, 
cefpirome, or cefepime, have not been shown to be supe- 
rior to cefotaxime or ceftriaxone. 
A repeat lumbar puncture, during the first 48 hours 
after initiation of therapy, is recommended in patients 
with pneumococcal meningitis, especially those with 
cephalosporin-resistant strains. The results of Gram stain 
and culture of CSF, at this interval, may be predictive of 
therapeutic success or failure.23 
Because severe cerebral edema appears to be a neg- 
ative prognostic factor in purulent meningitis, researchers 
have investigated the use of corticosteroids as adjunctive 
therapy.30z31 Several recent studies in children have 
demonstrated that the use of dexamethasone reduces 
hearing loss and other late neurologic sequelae associ- 
ated with bacterial meningitis. 
Though the effectiveness of adjunctive cortico- 
steroids has not been established in adults with purulent 
meningitis, their use should be considered in patients 
with advanced or rapidly progressive disease.32 Patients 
with positive Gram stains of CSF probably have advanced 
infection, as this test result indicates that massive num- 
bers of potentially pathogenic bacteria are present within 
their central nervous systems. Patients who present with 
loss of consciousness or any severe deficit in neurologic 
function or mental status also should be treated as 
advanced cases. 
The authors reviewed the outcome of pneumococ- 
cal meningitis in adults in Hospital General Vall d’Hebron 
who received adjunctive therapy with dexamethasone, 
starting from shortly before initiation of antimicrobial 
therapy and continuing for 48 hours.* Among these 
patients, the mortality rate was 13%; this is substantially 
lower than the 34% mortality rate seen in a historic con- 
trol group. Prospective controlled studies are needed to 
determine the role of steroids in the treatment of bacte- 
rial meningitis in adults. 
Immunization could prevent most cases of bacterial 
meningitis, but it is not widely available. When purulent 
meningitis is diagnosed, treatment with antibiotics and, 
in some cases, with adjunctive corticosteroids should be 
started as soon as possible. The choice of the best antibi- 
otic regimen may depend on local epidemiology and on 
individual results of culture and susceptibility tests. 
Aggressive and informed empirical therapy should reduce 
mortality among patients with purulent meningitis. 
REFERENCES 
1. Durand ML, Calderwood SB, Weber DJ, et al. Acute bacter- 
ial meningitis in adults. A review of 493 episodes. N Engl J 
Med 1993; 328:21-28. 
2. Bryan JP, de Silva MR, Tavares A, Rocha H, &held WM. Eti- 
ology and mortality of bacterial meningitis in northeastern 
Brazil. Rev Infect Dis 1990; 12:128-135. 
3. Wenger JD, Hightower AW, Facklam RR, et al. Bacterial 
meningitis in the United States, 1986: report of a multistate 
surveillance study. J Infect Dis 1990; 162:1316-1323. 
4. Almirante B, Cartes E, Pigrau C, et al. Therapy and outcome 
of pneumococcal meningitis in adults. A recent series of 70 
episodes. Med Clin @arc) 1995; 105:681-686. 
5. Tunkel AR, Scheld WM. Bacterial acute meningitis. Lancet 
1995; 346:1675-1680. 
Acute Purulent Meningitis / Almirante and CapdeviZa 181 
6. Spanos A, Hanell FE Jr, Durack DT Differential diagnosis of 
acute meningitis: an analysis of the predictive value of ini- 
tial observation. JAMA 1989; 262:2700-2707. 
7. Marton KI, Gean AD. The spinal tap: a new look at an old 
test. Ann Intern Med 1986; 104:840-848. 
8. Tunkel AR, Scheld WM. Acute bacterial meningitis in adults. 
Curr Clin Top Infect Dis 1996; 16:215-239. 
9. Sutcliffe EM, Jones DM, El-She&h S, Percival A. Penicillin- 
insensitive meningococci in the UK (Letter). Lancet 1988; 
1:657-658. 
10. Saez-Nieto JA, Lujan R, Berron S, et al. Epidemiology and 
molecular basis of penicillin-resistant Neisseria meningi- 
tidis in Spain: a 5-year history (1985-1989). Clin Infect Dis 
1992; 14:394-402. 
11. Almirante B, Ruiz-Cuevas P Pigrau C, Villalobos P Fernhn- 
dez E Pahissa A. Clinical significance and outcome of menin- 
gitis and sepsis caused by Neisseria meningitidis relatively 
resistant to penicillin (Nm RRP). In: Program and Abstracts 
of the 34th Interscience Conference on Antimicrobial 
Agents and Chemotherapy. Washington, DC: American Soci- 
ety for Microbiology, 1994: 12. 
12. Jackson LA, Tenover FC, Baker C, et al. Prevalence of Neis- 
seria meningitidis relatively resistant to penicillin in the 
United States, 1991. J Infect Dis 1994; 169:438-441. 
13. Perez-Trallero E, Garcia-Arensana JM, Ayestamn I, Mufioz- 
Baroja I. Comparative activity in vitro of I6 antimicrobial 
agents against penicillin-susceptible meningococci and 
meningococci with diminished susceptibility to penicillin. 
Antimicrob Agents Chemother 1989; 33:1622-1623. 
14. Campos J, Garcia Tornel S, Gairi JM, Fabreques I. Mutiply 
resistant Haemophilus influerzzae type b causing menin- 
gitis: comparative clinical and laboratory study. J Pediatr 
1989; 108:897-902. 
15. Almirante B, Planes AM, Pigrau C, de1 Valle 0, Pahissa A. 
Antimicrobial susceptibility and prognostic factors of inva- 
sive infections caused by Haemophilus in.uenzae (HI) in 
adults. In: Program and Abstracts of the 36th Interscience 
Conference on Antimicrobial Agents and Chemotherapy. 
Washington, DC: American Society for Microbiology, 
1996:271. 
16. Peltola J, Anttila M, Renkoven OV et al. Randomized com- 
parison of chloramphenicol, ampicillin, cefotaxime, and cef- 
triaxone for childhood bacterial meningitis. Lancet 1989; 
1:1281-1287. 
17. Lebel MH, Hoyt MJ, McCracken GH Jr. Comparative efficacy 
of ceftriaxone and cefuroxime for treatment of bacterial 
meningitis. J Pediatr 1989; 114:1049-1054. 
18. Schaad VB, Suter S, Gianella-Borradori A, et al. A compari- 
son of ceftriaxone and cefuroxime for the treatment of bac- 
terial meningitis in children. N Engl J Med 1990; 322: 
141-147. 
19. Appelbaum PC. Antimicrobial resistance in Streptococcus 
pneumoniae: an overview. Clin Infect Dis 1992; 15:77-83. 
20. Nava JM, Bella F, Garau J, et al. Predictive factors for inva- 
sive disease due to penicillin-resistant Streptococcus pneu- 
moniae: a population-based study. Clin Infect Dis 1994; 
19:884-890. 
2 1. MuHoz R, Musser JM, Crain M, et al. Geographic distribution 
of penicillin-resistant clones of Streptococcuspneumoniae: 
characterization by penicillin-binding protein profde, sur- 
face protein A typing and multilocus enzyme analysis. Clin 
Infect Dis 1992; 15:112-118. 
22. Soares D, Kristinsson KG, Musser JM, et al. Evidence for the 
introduction of a multiresistant clone of serotype 6B Strep- 
tococcus pneumoniae from Spain to Iceland in the late 
1980s. J Infect Dis 1993; 1683158-163. 
23. Paris MM, Ramilo 0, McCracken GH Jr. Management of 
meningitis caused by penicillin-resistant Streptococcus 
pneumoniae. Antimicrob Agents Chemother 1995; 39: 
2171-2175. 
24. National Committee for Clinical Laboratory Standards 
(NCCLS). Performance standards for antimicrobial suscep- 
tibility testing. Fifth Informational Supplement. NCCLS doc- 
ument MlO@S5 (ISBN l-56238-249-7) NCCLS, 771. Villanova, 
PA: NCCLS, 1994. 
25. Klugman KI? Pneumococcal resistance to third-generation 
cephalosporins: clinical, laboratory, and molecular aspects. 
Int J Antimicrob Agents 1994; 4:63-67. 
26. Hofmann J, Cetron MS, Farley MM, et al. The prevalence of 
drug-resistant Streptococcuspneumoniae in Atlanta. N Engl 
J Med 1995: 333:481-486. 
27. Linares J, Tubau E Cabellos C, et al. Increase of penicillin 
and third-generation cephalosporins resistance in meningeal 
isolates of Streptococcus pneumoniae in adult patients 
(1979-1994). In: Program and Abstracts of the 35th Inter- 
science Conference on Antimicrobial Agents and 
Chemotherapy. Washington, DC: American Society for 
Microbiology, 1995:89. 
28. Viladrich PF, Cabellos C, Pallares R, et al. High doses of cefo- 
taxime in treatment of adult meningitis due to Streptococcus 
pneumoniae with decreased susceptibilities to broad- 
spectrum cephalosporins. Antimicrob Agents Chemother 
1996; 40:218-220. 
29. Almirante B, Cartes E, Pigrau C, de1 Valle 0, Gasser I, Pahissa 
A. Clinical significance and outcome of meningitis caused 
by Streptococcuspneumoniae relatively resistant to broad- 
spectrum cephalosporins (Sp RRC). In: Program and 
Abstracts of the 35th Interscience Conference on Antimi- 
crobial Agents and Chemotherapy. Washington, DC: Amer- 
ican Society for Microbiology, 1995:289. 
30. Tauber MG, Khayam-Bashi H, Sande MA. Effects of ampi- 
cillin and corticosteroids on brain water-content, cere- 
brospinal fluid pressure, and cerebrospinal fluid lactate 
levels in experimental pneumococcal meningitis. J Infect 
Dis 1985; 151:528-534. 
31. Mustafa MM, Ramilo 0, Mertsola J, et al. Modulation of 
inflammation and cachectin activity in relation to treatment 
of experimental Haemophilus influenzae type b meningi- 
tis. J Infect Dis 1989; 160:818-825. 
32. Townsend GC, Scheld WM. The use of corticosteroids in the 
management of bacterial meningitis in adults. J Antimicrob 
Chemother 1996; 37:1051-1061. 
